Conditional Approval Act

Hozzl · 2022-10-28T01:46:13Z

Explore the details of Senate Bill 3133 Conditional Approval Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:46 AM

Congressional Summary of S 3133

Conditional Approval Act

This bill authorizes the Food and Drug Administration to conditionally approve certain new drugs intended for diseases that are seriously debilitating, life threatening, or chronic, and for which meaningful treatments do not exist. The bill also limits liability related to these conditionally approved drugs.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3133

Bill S 3133 is currently in the status of Bill Introduced since December 19, 2019. Bill S 3133 was introduced during Congress 116 and was introduced to the Senate on December 19, 2019. Bill S 3133's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of December 19, 2019

Bipartisan Support of Bill S 3133

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3133

Primary Policy Focus

Health

Potential Impact Areas

- Civil actions and liability

- Drug safety, medical device, and laboratory regulation

- Health care coverage and access

- Health information and medical records

- Licensing and registrations

- Marketing and advertising

- Medical research

Alternate Title(s) of Bill S 3133

Conditional Approval Act

A bill to amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs, and for other purposes.